Ironwood Pharmaceuticals_INT buy melinda
Start price
15.10.18
/
50%
?14.73
Target price
22.01.19
€16.24
Performance (%)
-24.58%
End price
22.01.19
€11.11
Summary
This prediction ended on 22.01.19 with a price of €11.11. The prediction for Ironwood Pharmaceuticals_INT disappointed with a performance of -24.58%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Ironwood Pharmaceuticals_INT | - | - | - | - |
| iShares Core DAX® | -3.429% | 5.085% | 15.455% | 12.600% |
| iShares Nasdaq 100 | -6.121% | 0.593% | 16.379% | 27.048% |
| iShares Nikkei 225® | -7.364% | 5.479% | 6.970% | -3.061% |
| iShares S&P 500 | -4.366% | 2.019% | 18.650% | 32.317% |
Comments by melinda for this prediction
In the thread Ironwood Pharmaceuticals diskutieren
SecteurRecherche biotechnologique et médicale Agenda 06/11 Publication de résultats
Discovers, develops, and intends to commercialize innovative human medicines
Ironwood Pharmaceuticals, Inc. operates as commercial biotechnology company, which discovers, develops and commercializes differentiated medicines that improve patient's lives.
Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout.
The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA.
Ironwood Pharmaceuticals, Inc. operates as commercial biotechnology company, which discovers, develops and commercializes differentiated medicines that improve patient's lives.
Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout.
The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA.
Nombre d'employés : 730 personnes.
(Vom Mitglied beendet)
Stopped prediction by melinda for Ironwood Pharmaceuticals_INT
Ironwood Pharmaceuticals_INT
Start price
Target price
Perf. (%)
?9.59
08.05.19
08.05.19
€11.09
19.06.19
19.06.19
15.66%
19.06.19
19.06.19
Ironwood Pharmaceuticals_INT
Start price
Target price
Perf. (%)
?15.33
21.07.17
21.07.17
€18.04
26.12.17
26.12.17
-9.88%
26.12.17
26.12.17
Ironwood Pharmaceuticals_INT
Start price
Target price
Perf. (%)
?8.97
19.06.13
19.06.13
€12.00
19.12.13
19.12.13
-13.51%
19.12.13
19.12.13
Ironwood Pharmaceuticals_INT
Start price
Target price
Perf. (%)
?7.53
04.10.10
04.10.10
€8.50
04.04.11
04.04.11
27.84%
04.04.11
04.04.11